SLC2A9 rs188405603: What Your Genotype Means
The rs188405603 variant is a genetic change located within the SLC2A9 gene. It has been identified in research as being associated with changes in triglyceride levels in patients treated with the antipsychotic medication quetiapine.
What each genotype means
Typical metabolic response
This genotype is considered the common or reference state in studied populations. Research suggests this variant may be associated with quetiapine-induced triglyceride changes, but evidence is limited and requires further replication. Please discuss any concerns regarding medication side effects or dosing with your clinician or pharmacist.
This genotype is common in most populations, though specific frequencies for this rare variant are not widely established.
Potential metabolic sensitivity
This genotype has been identified in research as potentially linked to changes in triglyceride levels when taking quetiapine. Because the evidence is limited and based on specific cohorts, it is unclear how this impacts your individual response. Please consult your healthcare provider or pharmacist before making any changes to your medication regimen.
This genotype is rare, appearing at low frequencies in the populations studied to date.
Potential metabolic sensitivity
This genotype has been identified in research as potentially linked to changes in triglyceride levels when taking quetiapine. Because the evidence is limited and based on specific cohorts, it is unclear how this impacts your individual response. Please consult your healthcare provider or pharmacist before making any changes to your medication regimen.
This genotype is very rare, appearing at very low frequencies in the populations studied to date.
Understanding the Variant and Gene
The rs188405603 variant is a single nucleotide polymorphism (SNP) located within an intron of the SLC2A9 gene. This gene encodes the protein glucose transporter 9 (GLUT9), which is primarily known for its role in the transport of urate and glucose within the kidney's proximal tubules. Because this variant sits in a non-coding intronic region, it is often studied for its potential regulatory effects on how the SLC2A9 gene is expressed or processed. While the variant itself does not change the protein structure directly, researchers investigate such SNPs to determine if they influence how an individual's body processes specific medications or metabolic pathways. In the context of pharmacogenomics, identifying these markers helps scientists understand why patients may experience different metabolic side effects when taking the same psychiatric treatments.
Research and Evidence Strength
Current evidence linking rs188405603 to quetiapine-induced triglyceride changes is considered limited. A genome-wide association study (GWAS) involving Chinese patients with schizophrenia identified this SNP as having a statistical association with triglyceride level fluctuations following quetiapine treatment. However, it is important to note that while the initial GWAS signal was significant, subsequent fine-mapping analyses in the same research context suggested that other nearby variants, such as rs77140241, might be the actual causal drivers of these metabolic changes. Because the evidence is based on specific cohorts and involves complex metabolic traits, the findings should be interpreted with caution. The field of pharmacogenomics is still evolving, and further large-scale, multi-ethnic studies are required to confirm whether this specific variant has a reliable, clinically actionable impact on how patients respond to antipsychotic therapy.
Clinical Context and Next Steps
It is vital to understand that this information is for educational purposes and does not constitute medical advice. Genetic variants like rs188405603 are just one of many factors—including diet, lifestyle, baseline health, and other medications—that influence how a person responds to a drug. You cannot use this information to diagnose a condition or make decisions about your medication regimen. If you are concerned about side effects, such as changes in your lipid profile while taking quetiapine, you must discuss these concerns with your clinician or pharmacist. They are the only ones qualified to evaluate your specific health history and determine if a change in dosage or treatment plan is appropriate for you. Never stop or alter your prescribed medication based on genetic test results without professional medical guidance.
How common is this variant?
The rs188405603 variant is considered rare in the general population, with frequency data varying significantly across different ancestral groups.
Frequently asked questions
What is the SLC2A9 gene?
The SLC2A9 gene provides instructions for making the GLUT9 protein, which helps transport glucose and uric acid in the body. It is primarily active in the kidneys.
Does this variant mean I will have side effects from quetiapine?
No. Genetic associations are statistical probabilities observed in groups, not individual predictions. Many factors influence drug response, and this variant is only one small piece of the puzzle.
Should I get tested for this variant?
There is currently no clinical recommendation to test for this variant. Pharmacogenetic testing is generally reserved for well-established markers with clear clinical guidelines.
What should I do if I am worried about my triglyceride levels?
You should schedule an appointment with your doctor to discuss your concerns. They can order standard blood tests to monitor your lipid levels and manage your health safely.
Sources & further reading
Educational information only, last refreshed 11/6/2026. Not medical advice — these associations describe population statistics, not individual predictions.
Curious what your genotype is for rs188405603?
Upload a raw DNA file from 23andMe, AncestryDNA, MyHeritage, or FamilyTreeDNA and see this variant — plus thousands more — interpreted in your full report.
Get my report — $29Related variants in SLC2A9
Functional variant in SLC2A9 significantly associated with serum uric acid levels and susceptibility to gout.
Common missense-associated variant in GLUT9 modulating serum urate homeostasis and risk of gout.
This SNP is linked to variations in serum uric acid levels and the risk of developing gout.
Increases the risk of high uric acid levels and gout.